Drug Profile
Vimseltinib - Deciphera Pharmaceuticals
Alternative Names: DCC 3014; DP-6865Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Giant cell tumour of tendon sheath
- Phase I/II Solid tumours
- No development reported Sarcoma